Results: A total of seven RCTs comprising 3915 patients with resectable stage NSCLC were randomized to chemotherapy with or without PD-1/PD-L1 inhibitors as NAT or AT. The gene discussed is BRD2; the disease is non-small cell lung carcinoma.